Jazz Pharmaceuticals Advances Phase 3 Xywav Dosing Study in Sleep Disorders
TipRanks (Wed, 19-Aug 12:31 PM ET)
Key deals this week: Workday, Diversified Energy, Aurora Cannabis, and more
Seeking Alpha News (Sat, 15-Aug 3:15 PM ET)
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
PRNewswire (Mon, 10-Aug 7:30 AM ET)
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
PRNewswire (Mon, 3-Aug 4:05 PM ET)
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
PRNewswire (Mon, 20-Jul 4:15 PM ET)
Business Wire (Wed, 17-Jun 7:00 AM ET)
PRNewswire (Tue, 16-Jun 4:05 PM ET)
PRNewswire (Fri, 12-Jun 8:00 AM ET)
PRNewswire (Thu, 4-Jun 7:45 AM ET)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Jazz Pharmaceuticals PLC - trades on the NASDAQ stock market under the symbol JAZZ.
As of August 19, 2026, JAZZ stock price declined to $252.10 with 455,167 million shares trading.
JAZZ has a beta of 0.15, meaning it tends to be less sensitive to market movements. JAZZ has a correlation of 0.00 to the broad based SPY ETF.
JAZZ has a market cap of $15.82 billion. This is considered a Large Cap stock.
Last quarter Jazz Pharmaceuticals PLC - reported $1 billion in Revenue and $5.71 earnings per share. This beat revenue expectation by $100 million and missed earnings estimates by -$.23.
In the last 3 years, JAZZ traded as high as $265.05 and as low as $95.49.
The top ETF exchange traded funds that JAZZ belongs to (by Net Assets): IJH, VTI, VB, VBR, VXF.
JAZZ has outperformed the market in the last year with a return of +114.2%, while the SPY ETF gained +20.7%. In the last 3 month period, JAZZ beat the market returning +9.8%, while SPY returned +4.4%. However, in the most recent 2 weeks JAZZ has underperformed the stock market by returning -3.6%, while SPY returned -0.3%.
JAZZ support price is $247.89 and resistance is $258.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JAZZ shares will trade within this expected range on the day.
